Andreas Hochhaus

发表

Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale.

Helen E White, Dong-Wook Kim, Timothy Hughes, 2013, Clinical chemistry.

Integration of mathematical model predictions into routine workflows to support clinical decision making in haematology

Ingo Roeder, Ingmar Glauche, Markus Loeffler, 2020, BMC Medical Informatics and Decision Making.

Key Data Elements in Myeloid Leukemia

Julian Varghese, Martin Dugas, Christian Holz, 2016, MIE.

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

Manuel Ayala, Ricardo Pasquini, Jorge Cortes, 2010, The New England journal of medicine.

The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA.

Nicholas C P Cross, Andreas Hochhaus, Pascual Bolufer, 2002, Human molecular genetics.

Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.

Philipp Erben, Christoph Walz, Carsten Müller-Tidow, 2011, Blood.

Liposomal encapsulated anti-cancer drugs.

Ulrich Beyer, Andreas Hochhaus, R. Hofheinz, 2005, Anti-cancer drugs.

Phase 1 study of INNO‐406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome‐positive leukemias after imatinib resistance or intolerance

Arnon Nagler, Jorge Cortes, Andreas Hochhaus, 2010, Cancer.

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Francisco Cervantes, Klaus Lechner, Thomas Fischer, 2003, The New England journal of medicine.

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.

Sante Tura, Thomas Fischer, Alois Gratwohl, 2002, Blood.

In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures.

Yi-Ching Hsieh, Knut Krohn, Andreas Hochhaus, 2005, Haematologica.

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.

Simona Soverini, Giovanni Martinelli, Thomas Ernst, 2011, Blood.

Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells.

Michaela Scherr, Andreas Hochhaus, Arnold Ganser, 2007, Blood.

Genotyping of 25 leukemia-associated genes in a single work flow by next-generation sequencing technology with low amounts of input template DNA.

Thomas Ernst, Alexander Kohlmann, Andreas Hochhaus, 2013, Clinical chemistry.

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.

Andreas Hochhaus, R. Collins, H. Kantarjian, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Francisco Cervantes, Simona Soverini, Giovanni Martinelli, 2013, Blood.

Activating CBL mutations are associated with a distinct MDS/MPN phenotype

Torsten Haferlach, Philipp Erben, Thomas Ernst, 2012, Annals of Hematology.

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

Francisco Cervantes, Alois Gratwohl, Giuseppe Saglio, 2006, Blood.

Impact of BCR-ABL mutations on patients with chronic myeloid leukemia

Thomas Ernst, Martin C. Müller, Andreas Hochhaus, 2011, Cell cycle.

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

Susan Branford, Andreas Hochhaus, Jaspal Kaeda, 2003, The New England journal of medicine.

Chronic myeloid leukaemia

Andreas Hochhaus, Rüdiger Hehlmann, M. Baccarani, 2007, The Lancet.

Chronic myelogenous leukemia: molecular and cellular aspects

Andreas Hochhaus, Rüdiger Hehlmann, R. Hehlmann, 1998, Journal of Cancer Research and Clinical Oncology.

BCR–ABL Transcript Dynamics Support the Hypothesis That Leukemic Stem Cells Are Reduced during Imatinib Treatment

Susan Branford, Andrew M. Stein, Dean Bottino, 2011, Clinical Cancer Research.

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Ricardo Pasquini, Giuseppe Saglio, Andreas Hochhaus, 2010, The New England journal of medicine.

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

Stefan W Krause, Alois Gratwohl, Claudia Haferlach, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA.

Paul Metcalfe, Helen E White, Susan Branford, 2010, Blood.

Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications

Ingo Roeder, Ingmar Glauche, Markus Loeffler, 2006, Nature Medicine.

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

James D. Griffin, Andreas Hochhaus, J. Griffin, 2007, Nature Reviews Cancer.

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.

Simona Soverini, Giovanni Martinelli, Susan Branford, 2006, Blood.

Long‐Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

Francisco Cervantes, Susan Branford, Andreas Hochhaus, 2017, The New England journal of medicine.

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Francisco Cervantes, Thomas Fischer, Alois Gratwohl, 2006, The New England journal of medicine.